Glycan microarrays containing synthetic Streptococcus pneumoniae CPS fragments 
and their application to vaccine development

Kaplonek, Paulina; Seeberger, Peter H.

doi:10.1007/978-1-0716-2148-6_12

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Book Chapter

Glycan microarrays containing synthetic Streptococcus pneumoniae CPS fragments and their application to vaccine development

MPS-Authors

/persons/resource/persons203549

Kaplonek, Paulina
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Kaplonek, P., & Seeberger, P. H. (2022). Glycan microarrays containing synthetic Streptococcus pneumoniae CPS fragments and their application to vaccine development. In J. M. Walker (Ed.), Methods in Molecular Biology (pp. 193-206). New York: Springer. doi:10.1007/978-1-0716-2148-6_12.

Cite as: https://hdl.handle.net/21.11116/0000-0009-B56D-1

Abstract

Streptococcus pneumoniae is the leading source of life-endangering diseases like pneumonia, septicemia, and meningitis, as well as a major cause of death in children under 5 years old in developing countries. At least 98 serotypes of S. pneumoniae can be distinguished based on their structurally distinct capsular polysaccharides (CPS). Currently available CPS-based pneumococcal vaccines contain serotypes most frequently associated with invasive pneumococcal diseases. The polysaccharides used in commercial conjugate-vaccines are isolated from bacteria cultures comprising many laborious and operationally challenging steps followed by depolymerization of long polysaccharides into small fragments and their conjugation to the carrier protein. The medicinal chemistry approach for glycoconjugate vaccine development offers an exciting alternative to CPS isolation for a broad range of different glycan antigens. Glycan arrays containing well-defined synthetic glycans of CPS fragments and repeating units are used as a platform for the high-throughput screening of various serum samples and identification of protective glycotopes for vaccine candidates.